Wed, Jan 28, 2015, 4:03 PM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Vertex Pharmaceuticals Incorporated Message Board

  • thirdmeinvestor thirdmeinvestor Nov 1, 2009 5:57 PM Flag

    Boc in PR

    The following direct quotes summarize its efficacy and safety.

    ... Based on an intent-to-treat analysis (ITT), the 28-week and 48-week lead-in boceprevir arms had SVR rates of 56 percent (58/103) and 75 percent (77/103), respectively, and the no lead-in boceprevir arms had SVR rates of 54 percent (58/107) and 67 percent (69/103), respectively, compared to 38 percent SVR for the control group.(3-5)...
    ... Treatment discontinuations due to adverse events were between 9 and 19 percent for patients in the boceprevir arms, compared to 8 percent for the control arm. Treatment discontinuations in the boceprevir arms due to viral breakthrough were fewer in the 28- and 48-week lead-in arms (4 and 5 percent, respectively) compared to the no lead-in arms (7 and 12 percent, respectively). ...

    http://finance.yahoo.com/news/Data-Supporting-Boceprevir-prnews-1677001601.html?x=0&.v=1

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • The raw data in the PR are not new. The data I quoted came from their new analysis of old data (SPRINT 1). The trial patients were entirely treatment-naive. Nevertheless, the PR uses the term null-responders for those patients who achieved less than one log drop in HCV counts after 4 wks of SOC. A null-responder was normally reserved for treatment-experienced patients who did not achieve 2 log drop at 12 wk treatment point.

 
VRTX
121.22-2.45(-1.98%)3:59 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.